An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma (Q63471462)

From Wikidata

Jump to navigation Jump to search

article

Language	Label	Description	Also known as
English	An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma	article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22569992%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22569992%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22569992%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

author name string

Pelin Bagci

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22569992%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Sameer H Patel

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22569992%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

David A Kooby

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22569992%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Bassel F El-Rayes

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22569992%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Charles A Staley

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22569992%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

N Volkan Adsay

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22569992%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Shishir K Maithel

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22569992%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

language of work or name

0 references

publication date

8 May 2012

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22569992%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22569992%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

119

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22569992%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22569992%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

445-453

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22569992%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant therapy of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Cellular pharmacology of gemcitabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular predictors of response to chemotherapy in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Ribonucleotide reductase small subunit M2B prognoses better survival in colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Progress in the development of prognostic and predictive markers for gastrointestinal malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

ERCC1: impact in multimodality treatment of upper gastrointestinal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret hospital Phase II consortium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.27619

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22569992%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22569992%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q63471462&oldid=1424921314"